Wordles Continued Popularity Highlights New York Times Digital Engagement Strategy Berkshire Hathaway Revamps Portfolio With Major Stakes in Delta Air Lines and Alphabet SpaceX Successfully Launches Starship on Second Attempt Advancing DeepSpace Ambitions US Productivity Growth Slows in Q4 While Unit Labor Costs Accelerate Japan Carmakers Face Margin Squeeze from Rising Aluminum Costs and Supply Risks UK Intelligence Chief Warns West Faces Moment of Consequence from RussiaChina Threats DMAC Q1 2026 Earnings WiderthanExpected Loss as Clinical Pipeline Advances Balchem Corporation Q1 2026 Earnings EPS Misses Estimates Amid Unchanged Stock Welltower Q1 2026 Earnings Strong EPS Beat of 318 Surprises Estimates GAING Q1 2026 Earnings Bond Issuer Misses EPS Estimate Amid Low Volatility Peoples Financial Services Corp Q1 2026 Earnings EPS Misses Estimates by 795 Stock Declines Green Dot Corporation Q1 2026 Earnings Strong EPS Beat Highlights Improving Profitability United Therapeutics UTHR Holds Steady Near 568 as Key Levels Come into Focus Neuphoria Therapeutics NEUP Soars 7 Key Levels to Watch After Bullish Breakout Atmus Filtration ATMU Edges Higher as Stock Holds Near Support Eyes Resistance at 5273 Antelope Enterprise Holdings AEHL Declines 11 as Selling Pressure Intensifies Spectral AI Inc Warrants MDAIW Hold Steady Near Support After Flat Session Mortgage Rate Outlook Bond Market Movements May Hold the Key GAU Q1 2026 Earnings Gold Producer Reports EPS Below Estimates Stock Gains Slightly Brookfield Renewable Partners BEP Holds Steady as Renewable Energy Sector Faces Mixed Signals PACK Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Stock Reaction BSY Q1 2026 Earnings EPS Beats Estimates by Nearly 6 CTS Q1 2026 Earnings Strong EPS Beat of 18 Drives Positive Stock Reaction INTS Q1 2026 Earnings NarrowerThanExpected Loss as PreRevenue Biotech Advances Clinical Pipeline HRI Q1 2026 Earnings Strong EPS Beat Surprises Market STAG Q1 2026 Earnings Stellar EPS Surprise Drives Cautious Optimism DRMA Q1 2026 Earnings NarrowerthanExpected Loss Marks Progress for ClinicalStage Biotech